Thu Sep 19 08:29:35 UTC 2024: ## Bausch + Lomb Holds Steady with Mixed Analyst Opinions
**New York, NY -** Bausch + Lomb (NYSE:BLCO), the eye health company, continues to receive mixed signals from analysts. While Needham & Company LLC reiterated their “hold” rating on the stock on Monday, several other firms have offered more bullish assessments.
Evercore lifted their price target on BLCO shares from $15.50 to $17.00, assigning an “in-line” rating. Similarly, Deutsche Bank Aktiengesellschaft raised their price target from $14.00 to $18.00, also maintaining a “hold” rating.
Meanwhile, HC Wainwright lowered their target price from $20.00 to $19.00 but maintained a “buy” rating, while Royal Bank of Canada reaffirmed their “outperform” rating with a $20.00 price objective.
Overall, six analysts have rated BLCO with a “hold” rating and six have assigned a “buy” rating, leading to a consensus “Moderate Buy” rating and an average price target of $18.59, according to MarketBeat.com.
Bausch + Lomb’s recent quarterly earnings results, released on July 31st, showed strong performance, with revenue exceeding analyst estimates and meeting earnings per share expectations. However, the company’s net margin remained negative.
Adding to the bullish sentiment, CEO Brent L. Saunders acquired 32,250 shares of Bausch + Lomb stock in a recent transaction, indicating confidence in the company’s future.
Institutional investors also demonstrate ongoing interest in BLCO, with several firms adjusting their holdings during recent quarters.
Bausch + Lomb operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The company’s global presence extends to the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and other international markets.
First Piper 